Rituximab Offlabel denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Rituximab Claim as Not FDA-Approved (for This Use)

Rituximab is FDA-approved for several specific indications. When your physician prescribes it for a condition outside those approved indications — an off-label use — BCBS may deny the claim on the grounds that the specific use lacks FDA approval. This is a distinct and narrower denial type than "experimental": FDA has not evaluated this specific use, but that does not mean the use lacks clinical support.

Off-label prescribing is legal, common, and often the standard of care in many specialties. BCBS's own coverage policies typically contain provisions allowing coverage of off-label uses that meet defined evidentiary criteria — published clinical evidence, specialty-society endorsement, or inclusion in recognized drug compendia. Your appeal should demonstrate that your use satisfies those provisions.

## Your Federal Appeal Rights

• Internal appeal: ERISA §503 (job-based plans) guarantees you access to the specific criteria applied and the right to respond with additional clinical evidence. File within the window on your denial letter.
• External review: ACA §2719 allows IRO review of adverse benefit determinations, including off-label denials. The typical filing window is four months from the final internal denial.
• Expedited option: Request simultaneously with your standard appeal if your clinical situation is urgent.

## Documentation to Gather

1. Diagnosis confirmation — complete specialist records establishing the exact diagnosis, including any pathology, imaging, or laboratory findings used to make it. 2. Evidence basis letter from prescriber — your physician should identify the recognized drug compendia (e.g., those referenced in your plan documents) and the specialty-society guideline organization (e.g., ACR, ASH, or the relevant subspecialty body) that support this off-label use. They should not need to cite specific statistics — recognition by a major guideline body is itself the standard. 3. BCBS off-label coverage criteria — obtain the current policy text governing off-label drug coverage. Most BCBS plans define an approved evidence tier (peer-reviewed publication, compendia listing, or guideline endorsement). Confirm your use satisfies at least one tier. 4. Prior-treatment history — relevant if the policy requires evidence that on-label alternatives were considered or tried. 5. Clinical severity documentation — chart records demonstrating the need for treatment and the appropriateness of this agent.

## Criteria-Mapping Structure

For each tier in BCBS's off-label coverage policy, prepare a one-sentence mapping: the specific evidence category, the source (guideline organization name, compendia name), and the chart or letter document confirming your use meets that tier. Attach the prescriber letter as the primary exhibit and the diagnosis records as supporting exhibits.